< 0 1 0 1 O
30 2 4 2 4 B-upper_bound
days 5 9 5 9 I-upper_bound
for 10 13 10 13 O
intravenously 14 27 14 27 O
- 27 28 27 28 O
administered 28 40 28 40 O
cytotoxic 41 50 41 50 B-treatment
chemotherapy 51 63 51 63 I-treatment
and/or 64 70 64 70 O
monoclonal 71 81 71 81 B-treatment
antibodies 82 92 82 92 I-treatment

< 0 1 93 94 O
5 2 3 95 96 B-upper_bound
half 4 8 97 101 O
- 8 9 101 102 O
lives 9 14 102 107 O
for 15 18 108 111 O
all 19 22 112 115 O
other 23 28 116 121 O
anti 29 33 122 126 B-treatment
- 33 34 126 127 I-treatment
cancer 34 40 127 133 I-treatment
agents 41 47 134 140 I-treatment
( 48 49 141 142 O
e.g. 49 53 142 146 O
, 53 54 146 147 O
targeted 55 63 148 156 B-treatment
therapies 64 73 157 166 I-treatment
, 73 74 166 167 O
corticosteroids 75 90 168 183 B-treatment
, 90 91 183 184 O
immunomodulatory 92 108 185 201 B-treatment
agents 109 115 202 208 I-treatment
, 115 116 208 209 O
etc 117 120 210 213 O
. 120 121 213 214 O
) 121 122 214 215 O

Active 0 6 216 222 O
central 7 14 223 230 B-cancer
nervous 15 22 231 238 I-cancer
system 23 29 239 245 I-cancer
lymphoma 30 38 246 254 I-cancer

Aspartate 0 9 255 264 B-clinical_variable
aminotransferase 10 26 265 281 I-clinical_variable
( 27 28 282 283 I-clinical_variable
AST)/alanine 28 40 283 295 I-clinical_variable
aminotransferase 41 57 296 312 I-clinical_variable
( 58 59 313 314 I-clinical_variable
ALT 59 62 314 317 I-clinical_variable
) 62 63 317 318 I-clinical_variable
< 64 65 319 320 O
3 66 67 321 322 B-upper_bound
x 68 69 323 324 I-upper_bound
upper 70 75 325 330 I-upper_bound
limit 76 81 331 336 I-upper_bound
of 82 84 337 339 I-upper_bound
normal 85 91 340 346 I-upper_bound
( 92 93 347 348 I-upper_bound
ULN 93 96 348 351 I-upper_bound
) 96 97 351 352 I-upper_bound

Bilirubin 0 9 353 362 B-clinical_variable
< 10 11 363 364 O
1.5 12 15 365 368 O
mg 16 18 369 371 O
/ 18 19 371 372 O
dL 19 21 372 374 O
with 22 26 375 379 O
the 27 30 380 383 O
exception 31 40 384 393 O
of 41 43 394 396 O
patients 44 52 397 405 O
thought 53 60 406 413 O
to 61 63 414 416 O
have 64 68 417 421 O
Gilbert 69 76 422 429 B-chronic_disease
's 76 78 429 431 I-chronic_disease
syndrome 79 87 432 440 I-chronic_disease
, 87 88 440 441 O
who 89 92 442 445 O
may 93 96 446 449 O
have 97 101 450 454 O
a 102 103 455 456 O
total 104 109 457 462 O
bilirubin 110 119 463 472 B-clinical_variable
above 120 125 473 478 O
1.5 126 129 479 482 O
mg 130 132 483 485 O
/ 132 133 485 486 O
dL 133 135 486 488 O

Creatinine 0 10 489 499 B-clinical_variable
( 11 12 500 501 I-clinical_variable
Cr 12 14 501 503 I-clinical_variable
) 14 15 503 504 I-clinical_variable
< 16 17 505 506 O
2.0 18 21 507 510 B-upper_bound

Fertile 0 7 511 518 O
men 8 11 519 522 B-gender
or 12 14 523 525 I-gender
women 15 20 526 531 I-gender
unwilling 21 30 532 541 B-contraception_consent
to 31 33 542 544 I-contraception_consent
use 34 37 545 548 I-contraception_consent
contraceptive 38 51 549 562 I-contraception_consent
techniques 52 62 563 573 I-contraception_consent
during 63 69 574 580 O
and 70 73 581 584 O
for 74 77 585 588 O
12 78 80 589 591 B-upper_bound
months 81 87 592 598 I-upper_bound
following 88 97 599 608 O
treatment 98 107 609 618 O

High 0 4 619 623 B-treatment
- 4 5 623 624 I-treatment
dose 5 9 624 628 I-treatment
chemotherapy 10 22 629 641 I-treatment
or 23 25 642 644 O
external 26 34 645 653 B-treatment
beam 35 39 654 658 I-treatment
radiation 40 49 659 668 I-treatment
therapy 50 57 669 676 I-treatment
to 58 60 677 679 I-treatment
lung 61 65 680 684 I-treatment
, 65 66 684 685 I-treatment
liver 67 72 686 691 I-treatment
, 72 73 691 692 I-treatment
or 74 76 693 695 I-treatment
kidneys 77 84 696 703 I-treatment
> 85 86 704 705 O
20 87 89 706 708 B-lower_bound
Gy 90 92 709 711 I-lower_bound
within 93 99 712 718 O
the 100 103 719 722 O
previous 104 112 723 731 B-upper_bound
100 113 116 732 735 I-upper_bound
days 117 121 736 740 I-upper_bound
prior 122 127 741 746 B-treatment
to 128 130 747 749 I-treatment
therapeutic 131 142 750 761 I-treatment
90Y 143 146 762 765 I-treatment
- 146 147 765 766 I-treatment
ibritumomab 147 158 766 777 I-treatment
tiuxetan 159 167 778 786 I-treatment
dose 168 172 787 791 I-treatment

Medical 0 7 792 799 B-chronic_disease
condition 8 17 800 809 I-chronic_disease
that 18 22 810 814 O
would 23 28 815 820 O
contraindicate 29 43 821 835 O
allogeneic 44 54 836 846 B-treatment
transplantation 55 70 847 862 I-treatment
as 71 73 863 865 O
per 74 77 866 869 O
standard 78 86 870 878 O
practice 87 95 879 887 O
guidelines 96 106 888 898 O
( 107 108 899 900 O
e.g. 108 112 900 904 O
, 112 113 904 905 O
impaired 114 122 906 914 B-chronic_disease
cardiopulmonary 123 138 915 930 I-chronic_disease
function 139 147 931 939 I-chronic_disease
, 147 148 939 940 O
hepatitis 149 158 941 950 B-chronic_disease
, 158 159 950 951 O
etc 160 163 952 955 O
) 163 164 955 956 O

Patients 0 8 957 965 O
must 9 13 966 970 O
have 14 18 971 975 O
a 19 20 976 977 O
histologically 21 35 978 992 O
confirmed 36 45 993 1002 O
diagnosis 46 55 1003 1012 O
of 56 58 1013 1015 O
aggressive 59 69 1016 1026 O
B 70 71 1027 1028 B-cancer
- 71 72 1028 1029 I-cancer
cell 72 76 1029 1033 I-cancer
lymphoma 77 85 1034 1042 I-cancer
( 86 87 1043 1044 O
diffuse 87 94 1044 1051 B-cancer
large 95 100 1052 1057 I-cancer
B 101 102 1058 1059 I-cancer
- 102 103 1059 1060 I-cancer
cell 103 107 1060 1064 I-cancer
lymphoma 108 116 1065 1073 I-cancer
[ 117 118 1074 1075 I-cancer
DLBCL 118 123 1075 1080 I-cancer
] 123 124 1080 1081 I-cancer
, 124 125 1081 1082 O
Burkitt 126 133 1083 1090 B-cancer
lymphoma 134 142 1091 1099 I-cancer
[ 143 144 1100 1101 I-cancer
BL 144 146 1101 1103 I-cancer
] 146 147 1103 1104 I-cancer
, 147 148 1104 1105 O
etc 149 152 1106 1109 O
. 152 153 1109 1110 O
) 153 154 1110 1111 O
expressing 155 165 1112 1122 O
the 166 169 1123 1126 O
CD20 170 174 1127 1131 O
antigen 175 182 1132 1139 O
and 183 186 1140 1143 O
have 187 191 1144 1148 O
failed 192 198 1149 1155 O
at 199 201 1156 1158 O
least 202 207 1159 1164 O
one 208 211 1165 1168 B-lower_bound
prior 212 217 1169 1174 B-treatment
standard 218 226 1175 1183 I-treatment
systemic 227 235 1184 1192 I-treatment
therapy 236 243 1193 1200 I-treatment

Patients 0 8 1201 1209 O
must 9 13 1210 1214 O
have 14 18 1215 1219 O
an 19 21 1220 1222 O
HLA 22 25 1223 1226 B-clinical_variable
- 25 26 1226 1227 O
identical 26 35 1227 1236 O
related 36 43 1237 1244 O
or 44 46 1245 1247 O
HLA 47 50 1248 1251 O
- 50 51 1251 1252 O
matched 51 58 1252 1259 O
unrelated 59 68 1260 1269 O
donor 69 74 1270 1275 O

Patients 0 8 1276 1284 O
must 9 13 1285 1289 O
have 14 18 1290 1294 O
an 19 21 1295 1297 O
expected 22 30 1298 1306 O
survival 31 39 1307 1315 O
without 40 47 1316 1323 O
treatment 48 57 1324 1333 B-treatment
of 58 60 1334 1336 O
> 61 62 1337 1338 O
60 63 65 1339 1341 B-lower_bound
days 66 70 1342 1346 I-lower_bound
and 71 74 1347 1350 O
must 75 79 1351 1355 O
be 80 82 1356 1358 O
free 83 87 1359 1363 O
of 88 90 1364 1366 O
major 91 96 1367 1372 O
infection 97 106 1373 1382 B-chronic_disease
including 107 116 1383 1392 O
human 117 122 1393 1398 B-chronic_disease
immunodeficiency 123 139 1399 1415 I-chronic_disease
virus 140 145 1416 1421 I-chronic_disease
( 146 147 1422 1423 I-chronic_disease
HIV 147 150 1423 1426 I-chronic_disease
) 150 151 1426 1427 I-chronic_disease

Patients 0 8 1428 1436 O
must 9 13 1437 1441 O
have 14 18 1442 1446 O
relapsed 19 27 1447 1455 O
after 28 33 1456 1461 O
high 34 38 1462 1466 B-treatment
- 38 39 1466 1467 I-treatment
dose 39 43 1467 1471 I-treatment
therapy 44 51 1472 1479 I-treatment
and 52 55 1480 1483 O
autologous 56 66 1484 1494 B-treatment
transplantation 67 82 1495 1510 I-treatment
or 83 85 1511 1513 O
be 86 88 1514 1516 O
ineligible 89 99 1517 1527 O
for 100 103 1528 1531 O
high 104 108 1532 1536 O
- 108 109 1536 1537 O
dose 109 113 1537 1541 O
therapy 114 121 1542 1549 O
and 122 125 1550 1553 O
autologous 126 136 1554 1564 O
transplantation 137 152 1565 1580 O
; 152 153 1580 1581 O
patients 154 162 1582 1590 O
that 163 167 1591 1595 O
have 168 172 1596 1600 O
failed 173 179 1601 1607 O
autologous 180 190 1608 1618 O
transplantation 191 206 1619 1634 O
are 207 210 1635 1638 O
those 211 216 1639 1644 O
with 217 221 1645 1649 O
persistent 222 232 1650 1660 O
disease 233 240 1661 1668 O
> 241 242 1669 1670 O
30 243 245 1671 1673 B-lower_bound
days 246 250 1674 1678 I-lower_bound
after 251 256 1679 1684 I-lower_bound
transplant 257 267 1685 1695 O
; 267 268 1695 1696 O
those 269 274 1697 1702 O
ineligible 275 285 1703 1713 O
for 286 289 1714 1717 O
autologous 290 300 1718 1728 O
transplant 301 311 1729 1739 O
include 312 319 1740 1747 O
those 320 325 1748 1753 O
with 326 330 1754 1758 O
chemoresistant 331 345 1759 1773 B-cancer
disease 346 353 1774 1781 I-cancer
( 354 355 1782 1783 O
i.e. 355 359 1783 1787 O
, 359 360 1787 1788 O
patients 361 369 1789 1797 O
who 370 373 1798 1801 O
have 374 378 1802 1806 O
not 379 382 1807 1810 O
achieved 383 391 1811 1819 O
a 392 393 1820 1821 O
partial 394 401 1822 1829 O
response 402 410 1830 1838 O
or 411 413 1839 1841 O
better 414 420 1842 1848 O
with 421 425 1849 1853 O
their 426 431 1854 1859 O
most 432 436 1860 1864 O
recent 437 443 1865 1871 O
chemotherapy 444 456 1872 1884 B-treatment
regimen 457 464 1885 1892 I-treatment
) 464 465 1892 1893 O
, 465 466 1893 1894 O
are 467 470 1895 1898 O
expected 471 479 1899 1907 O
to 480 482 1908 1910 O
have 483 487 1911 1915 O
a 488 489 1916 1917 O
poor 490 494 1918 1922 O
outcome 495 502 1923 1930 O
from 503 507 1931 1935 O
autologous 508 518 1936 1946 O
transplant 519 529 1947 1957 O
( 530 531 1958 1959 O
e.g. 531 535 1959 1963 O
, 535 536 1963 1964 O
DLBCL 537 542 1965 1970 B-cancer
relapsing 543 552 1971 1980 O
within 553 559 1981 1987 O
one 560 563 1988 1991 B-upper_bound
year 564 568 1992 1996 I-upper_bound
of 569 571 1997 1999 O
rituximab 572 581 2000 2009 B-treatment
, 581 582 2009 2010 O
cyclophosphamide 583 599 2011 2027 B-treatment
, 599 600 2027 2028 O
doxorubicin 601 612 2029 2040 B-treatment
hydrochloride 613 626 2041 2054 I-treatment
, 626 627 2054 2055 O
vincristine 628 639 2056 2067 B-treatment
sulfate 640 647 2068 2075 I-treatment
, 647 648 2075 2076 O
prednisone 649 659 2077 2087 B-treatment
[ 660 661 2088 2089 I-treatment
R 661 662 2089 2090 I-treatment
- 662 663 2090 2091 I-treatment
CHOP]-like 663 673 2091 2101 I-treatment
chemotherapy 674 686 2102 2114 I-treatment
, 686 687 2114 2115 O
double 688 694 2116 2122 B-cancer
hit 695 698 2123 2126 I-cancer
lymphoma 699 707 2127 2135 I-cancer
, 707 708 2135 2136 O
v 709 710 2137 2138 O
- 710 711 2138 2139 O
myc 711 714 2139 2142 O
myelocytomatosis 715 731 2143 2159 O
viral 732 737 2160 2165 O
oncogene 738 746 2166 2174 O
homolog 747 754 2175 2182 O
( 755 756 2183 2184 O
avian 756 761 2184 2189 O
) 761 762 2189 2190 O
positive 763 771 2191 2199 O
[ 772 773 2200 2201 O
MYC+ 773 777 2201 2205 O
] 777 778 2205 2206 O
lymphoma 779 787 2207 2215 O
, 787 788 2215 2216 O
persistent 789 799 2217 2227 O
positron 800 808 2228 2236 B-treatment
emission 809 817 2237 2245 I-treatment
tomography 818 828 2246 2256 I-treatment
[ 829 830 2257 2258 I-treatment
PET 830 833 2258 2261 I-treatment
] 833 834 2261 2262 I-treatment
positivity 835 845 2263 2273 O
after 846 851 2274 2279 O
chemotherapy 852 864 2280 2292 O
) 864 865 2292 2293 O
, 865 866 2293 2294 O
are 867 870 2295 2298 O
unable 871 877 2299 2305 O
to 878 880 2306 2308 O
collect 881 888 2309 2316 O
sufficient 889 899 2317 2327 O
or 900 902 2328 2330 O
tumor 903 908 2331 2336 B-cancer
- 908 909 2336 2337 O
free 909 913 2337 2341 O
autologous 914 924 2342 2352 B-treatment
stem 925 929 2353 2357 I-treatment
cells 930 935 2358 2363 I-treatment
per 936 939 2364 2367 O
Seattle 940 947 2368 2375 O
Cancer 948 954 2376 2382 O
Care 955 959 2383 2387 O
Alliance 960 968 2388 2396 O
( 969 970 2397 2398 O
SCCA 970 974 2398 2402 O
) 974 975 2402 2403 O
standard 976 984 2404 2412 O
practice 985 993 2413 2421 O
, 993 994 2421 2422 O
are 995 998 2423 2426 O
unable 999 1005 2427 2433 O
to 1006 1008 2434 2436 O
tolerate 1009 1017 2437 2445 O
the 1018 1021 2446 2449 O
high 1022 1026 2450 2454 B-treatment
- 1026 1027 2454 2455 I-treatment
dose 1027 1031 2455 2459 I-treatment
autologous 1032 1042 2460 2470 I-treatment
conditioning 1043 1055 2471 2483 I-treatment
regimens 1056 1064 2484 2492 I-treatment
, 1064 1065 2492 2493 O
or 1066 1068 2494 2496 O
who 1069 1072 2497 2500 O
refuse 1073 1079 2501 2507 O
a 1080 1081 2508 2509 O
high 1082 1086 2510 2514 B-treatment
- 1086 1087 2514 2515 I-treatment
dose 1087 1091 2515 2519 I-treatment
autologous 1092 1102 2520 2530 I-treatment
transplant 1103 1113 2531 2541 I-treatment
regimen 1114 1121 2542 2549 I-treatment

Pregnancy 0 9 2550 2559 B-pregnancy

Receipt 0 7 2560 2567 O
of 8 10 2568 2570 O
systemic 11 19 2571 2579 B-treatment
anti 20 24 2580 2584 I-treatment
- 24 25 2584 2585 I-treatment
lymphoma 25 33 2585 2593 I-treatment
therapy 34 41 2594 2601 I-treatment
withinthe 42 51 2602 2611 O
following 52 61 2612 2621 O
intervals 62 71 2622 2631 O
prior 72 77 2632 2637 O
to 78 80 2638 2640 O
the 81 84 2641 2644 O
therapeutic 85 96 2645 2656 B-treatment
90Y 97 100 2657 2660 I-treatment
- 100 101 2660 2661 I-treatment
ibritumomab 101 112 2661 2672 I-treatment
tiuxetan 113 121 2673 2681 I-treatment
dose 122 126 2682 2686 O

Southwest 0 9 2687 2696 B-clinical_variable
Oncology 10 18 2697 2705 I-clinical_variable
Group 19 24 2706 2711 I-clinical_variable
( 25 26 2712 2713 I-clinical_variable
SWOG)/Eastern 26 39 2713 2726 I-clinical_variable
Cooperative 40 51 2727 2738 I-clinical_variable
Oncology 52 60 2739 2747 I-clinical_variable
Group 61 66 2748 2753 I-clinical_variable
( 67 68 2754 2755 I-clinical_variable
ECOG 68 72 2755 2759 I-clinical_variable
) 72 73 2759 2760 I-clinical_variable
performance 74 85 2761 2772 I-clinical_variable
score 86 91 2773 2778 I-clinical_variable
> 92 93 2779 2780 O
= 93 94 2780 2781 O
2 95 96 2782 2783 B-lower_bound

